Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases; Breast cancer
- Focus Pharmacodynamics
- 13 Feb 2017 Status changed from active, no longer recruiting to recruiting.
- 09 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Feb 2015 Planned primary completion date changed from 1 Nov 2019 to 1 Feb 2020 as reported by ClinicalTrials.gov